ZA811503B - Substituted cyclo-hebtenes, their preparation, and therapetic agents containing these compounds - Google Patents

Substituted cyclo-hebtenes, their preparation, and therapetic agents containing these compounds

Info

Publication number
ZA811503B
ZA811503B ZA00811503A ZA811503A ZA811503B ZA 811503 B ZA811503 B ZA 811503B ZA 00811503 A ZA00811503 A ZA 00811503A ZA 811503 A ZA811503 A ZA 811503A ZA 811503 B ZA811503 B ZA 811503B
Authority
ZA
South Africa
Prior art keywords
compounds
preparation
agents containing
hebtenes
substituted cyclo
Prior art date
Application number
ZA00811503A
Other languages
English (en)
Inventor
G Steiner
H Hofmann
H Kreiskott
H Teschendorf
D Lenke
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA811503B publication Critical patent/ZA811503B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Anesthesiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Polyesters Or Polycarbonates (AREA)
ZA00811503A 1980-03-08 1981-03-06 Substituted cyclo-hebtenes, their preparation, and therapetic agents containing these compounds ZA811503B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19803009034 DE3009034A1 (de) 1980-03-08 1980-03-08 10-substituierte 5-cyanmethylendibenzo (a,d) -cycloheptne

Publications (1)

Publication Number Publication Date
ZA811503B true ZA811503B (en) 1982-04-28

Family

ID=6096682

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA00811503A ZA811503B (en) 1980-03-08 1981-03-06 Substituted cyclo-hebtenes, their preparation, and therapetic agents containing these compounds

Country Status (12)

Country Link
US (2) US4447610A (da)
EP (1) EP0035711B1 (da)
JP (1) JPS56139446A (da)
AT (1) ATE7391T1 (da)
AU (1) AU536527B2 (da)
CA (1) CA1163265A (da)
DE (2) DE3009034A1 (da)
DK (1) DK161456C (da)
FI (1) FI75155C (da)
IE (1) IE51017B1 (da)
NO (1) NO155620C (da)
ZA (1) ZA811503B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4041463A1 (de) * 1990-12-22 1992-06-25 Basf Ag 5-cyanmethylen-10-(piperazin-1-yl)-dibenzo(a,d)cycloheptene zur bekaempfung der migraene
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1568089A1 (de) * 1951-01-28 1970-01-02 Boehringer Mannheim Gmbh Verfahren zur Herstellung tricyclischer AEthylamin-Derivate
FR1332145A (da) * 1961-06-08 1963-12-16
FR111F (da) * 1964-03-27
BE664608A (da) * 1964-05-29
US3846431A (en) * 1965-01-08 1974-11-05 Spiegelberg H Heterocyclically dibenzo(a,d)cyclohepta(1,4)dien-5-one derivatives
NL152845B (nl) * 1966-03-11 1977-04-15 Boehringer Mannheim Gmbh Werkwijze voor het bereiden van een geneesmiddel met een psychotrope en bloedsomloopstimulerende werking, alsmede het aldus verkregen gevormde geneesmiddel, en werkwijze voor het bereiden van een geneeskrachtig omega,omega-difenylalkylaminederivaat.
US3459806A (en) * 1968-02-07 1969-08-05 Sandoz Ag Benzobenzazulenes
CA1000701A (en) * 1972-07-19 1976-11-30 Leslie G. Humber Process for preparing hexahydrobenzo (6,7) cyclohepta(1,2,3-de)isoquinolines
US4399141A (en) * 1977-09-19 1983-08-16 Merck & Co., Inc. 5-Alkyl or hydroxyalkyl substituted-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines and anticonvulsant use thereof
DE2918778A1 (de) * 1979-05-10 1980-11-20 Basf Ag 6-substituierte 11-alkylen-morphantridine

Also Published As

Publication number Publication date
EP0035711A3 (en) 1982-01-20
NO810761L (no) 1981-09-09
NO155620B (no) 1987-01-19
ATE7391T1 (de) 1984-05-15
FI75155C (fi) 1988-05-09
EP0035711B1 (de) 1984-05-09
NO155620C (no) 1987-04-29
DK161456B (da) 1991-07-08
FI75155B (fi) 1988-01-29
AU6813981A (en) 1981-09-17
IE810493L (en) 1981-09-08
EP0035711A2 (de) 1981-09-16
CA1163265A (en) 1984-03-06
AU536527B2 (en) 1984-05-10
DE3009034A1 (de) 1981-09-24
DE3163457D1 (en) 1984-06-14
DK161456C (da) 1991-12-16
IE51017B1 (en) 1986-09-03
JPS56139446A (en) 1981-10-30
JPS6411014B2 (da) 1989-02-23
FI810643L (fi) 1981-09-09
DK101781A (da) 1981-09-09
US4548933A (en) 1985-10-22
US4447610A (en) 1984-05-08

Similar Documents

Publication Publication Date Title
GB2316004B (en) Novel formulations for transdermal delivery of pergolide
GR3017367T3 (en) composition in the form of a foam containing 5-aminosalicylic acid for intra-rectal administration.
MY128809A (en) Pharmaceutical formulation of omeprazole
GR3029308T3 (en) Medical device for the administration of active ingredients or drugs at very low doses, particularly homeopathic drugs.
GEP20002229B (en) Synthetic Membrane Vesicles, Method for Obtaining and Application of the Same
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
DE3474774D1 (en) Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
AU533524B2 (en) 6-substituted-11-alkylene morphanthridines
ZA811503B (en) Substituted cyclo-hebtenes, their preparation, and therapetic agents containing these compounds
ZA81927B (en) Phenylpiperazine derivatives of 1,3,4-oxadiazolyphenols their preparation and therapeutic agents containing these compounds
AU2908389A (en) Device for administering medicaments by atomization in intubated or tracheotomized patients
DE3166888D1 (en) 10-substituted-5-cyanomethylene-10,11-dihydro-dibenzo-(a,d)-cycloheptenes, process for their preparation and pharmaceutical compositions containing them
EP0190860A3 (en) 6-chloro-3-methyl-1h-2,3,4,5-tetrahydro-3-benzazepine-n-oxide and medical compositions using it
AU6037494A (en) Use of active substances in the therapy of certain diseases, process for preparing a pharmaceutical composition for that purpose and pharmaceutical compositions thus prepared
EP0311467A3 (en) Use of pyrroloû3,2,1-hi¨indole derivatives in the manufacture of a medicament for the treatment of diabetes
IT1255380B (it) Nitrobenzoilalanine,procedimento per la loro preparazione,loro uso come agenti terapeutici e composizioni farmaceutiche che le contengono
ZA944103B (en) Dosage form for administering drug in liquid formulation